A selective second-generation Nav1.8 inhibitor, FZ008-145 is designed to provide non-addictive pain relief. This Nav1.8 target has been clinically validated in five acute pain and one chronic pain
The treatment is indicated for use in PD patients experiencing severe motor fluctuations and hyperkinesia or dyskinesia. This marks the introduction of the first 24-hour continuous subcutaneous infusion
The deal, facilitated by Johnson & Johnson Innovation, will enable Janssen to develop cell therapies that are armed with DR-18 of Simcha. Janssen will be responsible for the
B244, which is presently being readied for international Phase III clinical trials, is a therapeutic treatment aimed at inflammatory indications such as atopic dermatitis, addressing both appearance and
The facility, which is part of the company’s strategic growth plan, aims to enhance pharmaceutical development and manufacturing offerings in Asia. This will aid in meeting the increasing
This therapy is designed for the treatment of multiple sclerosis (MS), a chronic neurodegenerative autoimmune disease. CAR T-cell therapy involves modifying a patient’s T cells to target and
This partnership covers drug-linker technology and CRDMO services right from discovery to commercialisation. WuXi XDC CEO Dr. Jimmy Li said, “IntoCell’s unique drug-linker technologies and our leading, open-access
This development is part of Galapagos’ strategy to transform into a new biotechnology enterprise with a robust research and development pipeline for treating disease immunology and oncology fields.
Received through the foundation’s Inflammatory Bowel Disease (IBD) Ventures programme, this payment is part of a priorly disclosed grant under research programme agreement with Giiant Pharma to support
In October this year, Lilly signed a definitive agreement for POINT Biopharma acquisition. POINT Biopharma focuses on developing radioligand treatments for cancer and has a pipeline of such
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.